Observational studyJournal of neurology2026
Subcutaneous natalizumab administration in relapsing-remitting multiple sclerosis: results of EASIER 2 study.
Observational study in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEASIER 2 is a multicenter, observational, cross-sectional study conducted in 14 Italian multiple sclerosis (MS) centers to evaluate patient and healthcare professional (HCP) time, healthcare resource consumption, costs, and patient quality of life (QoL) associated with subcutaneous (SC) administration of natalizumab compared to intravenous (IV) administration as measured in the earlier EASIER study.
methodsThe study included: (1) time-and-motion analysis using a mobile application to collect real-world data during SC administration; (2) structured HCP questionnaire assessing organizational impacts; (3) patient survey capturing experience, preferences, and QoL. The comparison between SC and IV was conducted using a random-intercept regression model adjusted for patient history.
resultsA total of 265 SC procedures were analyzed. Compared to IV administration, SC reduced patient center time by 77%, HCP active time by 35%, and chair time by 74%. Hospital costs per administration decreased by 60%, with a reduction of about 33 and 14% from the perspectives of the Society and patient, respectively. Among patients, 86% preferred SC administration, mainly due to shorter center time, less physical discomfort, and lower emotional burden. QoL scores (scale 0-100) were higher on SC days (mean 70.4) than IV days (mean 56.9) administration, corresponding to a 13-point improvement (p < 0.001). All HCPs reported a favorable opinion on SC administration, with 82% expecting simplifications in MS center organization and shorter patient waiting lists.
conclusionsSC natalizumab administration significantly reduces dispensation procedure times, healthcare resource consumption, and associated costs, while improving patient experience and QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.